UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Pathogenesis of IgA nephropathy

Authors
Jonathan Barratt, PhD, FRCP
John Feehally, DM, FRCP
Section Editors
Richard J Glassock, MD, MACP
Fernando C Fervenza, MD, PhD
Deputy Editor
Albert Q Lam, MD

INTRODUCTION

IgA nephropathy is the most common lesion found to cause primary glomerulonephritis throughout most developed countries of the world [1-8]. IgA deposits may also be seen on kidney biopsy in individuals with no evidence of renal disease [9]. The reported incidence of mesangial IgA deposition in apparently healthy individuals ranges from 3 to 16 percent [9,10]. These cases had no clinical features of nephritis but their renal biopsy was consistent with IgA nephropathy.

This observation raises three important points:

There is a large cohort of undiagnosed "latent" IgA nephropathy in the general population.

This must be taken into account when genetic studies are undertaken comparing gene polymorphisms in IgAN with normal "healthy" populations.

It raises an important consideration for the pathogenesis of IgA nephropathy: the process of mesangial IgA deposition is likely to be separate from the induction of glomerular injury and IgA deposition does not necessarily need to be followed by nephritis. Identifying the factors common to both processes is essential to our overall understanding of the pathogenesis of IgAN.

                  

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Fri Jul 24 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med 2013; 368:2402.
  2. D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 2004; 24:179.
  3. Emancipator SN. IgA nephropathy: morphologic expression and pathogenesis. Am J Kidney Dis 1994; 23:451.
  4. Galla JH. IgA nephropathy. Kidney Int 1995; 47:377.
  5. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002; 347:738.
  6. Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int 2004; 66:920.
  7. Simon P, Ramee MP, Boulahrouz R, et al. Epidemiologic data of primary glomerular diseases in western France. Kidney Int 2004; 66:905.
  8. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol 2005; 16:2088.
  9. Suzuki K, Honda K, Tanabe K, et al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 2003; 63:2286.
  10. Waldherr R, Rambausek M, Duncker WD, Ritz E. Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant 1989; 4:943.
  11. Oortwijn BD, Rastaldi MP, Roos A, et al. Demonstration of secretory IgA in kidneys of patients with IgA nephropathy. Nephrol Dial Transplant 2007; 22:3191.
  12. Lee HS, Choi Y, Lee JS, et al. Ultrastructural changes in IgA nephropathy in relation to histologic and clinical data. Kidney Int 1989; 35:880.
  13. Barratt J, Feehally J, Smith AC. Pathogenesis of IgA nephropathy. Semin Nephrol 2004; 24:197.
  14. Hiki Y, Odani H, Takahashi M, et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 2001; 59:1077.
  15. Allen AC, Bailey EM, Brenchley PE, et al. Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int 2001; 60:969.
  16. Smith AC, Molyneux K, Feehally J, Barratt J. O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy. J Am Soc Nephrol 2006; 17:3520.
  17. Berthoux F, Suzuki H, Thibaudin L, et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 2012; 23:1579.
  18. Lau KK, Wyatt RJ, Moldoveanu Z, et al. Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura. Pediatr Nephrol 2007; 22:2067.
  19. Suzuki H, Moldoveanu Z, Hall S, et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest 2008; 118:629.
  20. Novak J, Julian BA, Tomana M, Mestecky J. IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin Nephrol 2008; 28:78.
  21. Suzuki H, Fan R, Zhang Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 2009; 119:1668.
  22. Tomana M, Novak J, Julian BA, et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 1999; 104:73.
  23. Kokubo T, Hiki Y, Iwase H, et al. Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins. J Am Soc Nephrol 1998; 9:2048.
  24. Gharavi AG, Moldoveanu Z, Wyatt RJ, et al. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 2008; 19:1008.
  25. Feehally J, Farrall M, Boland A, et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol 2010; 21:1791.
  26. Gharavi AG, Kiryluk K, Choi M, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011; 43:321.
  27. Yu XQ, Li M, Zhang H, et al. A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet 2011; 44:178.
  28. Serino G, Sallustio F, Cox SN, et al. Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J Am Soc Nephrol 2012; 23:814.
  29. Harper SJ, Pringle JH, Wicks AC, et al. Expression of J chain mRNA in duodenal IgA plasma cells in IgA nephropathy. Kidney Int 1994; 45:836.
  30. Westberg NG, Baklien K, Schmekel B, et al. Quantitation of immunoglobulin-producing cells in small intestinal mucosa of patients with IgA nephropathy. Clin Immunol Immunopathol 1983; 26:442.
  31. Harper SJ, Allen AC, Pringle JH, Feehally J. Increased dimeric IgA producing B cells in the bone marrow in IgA nephropathy determined by in situ hybridisation for J chain mRNA. J Clin Pathol 1996; 49:38.
  32. van den Wall Bake AW, Daha MR, Evers-Schouten J, van Es LA. Serum IgA and the production of IgA by peripheral blood and bone marrow lymphocytes in patients with primary IgA nephropathy: evidence for the bone marrow as the source of mesangial IgA. Am J Kidney Dis 1988; 12:410.
  33. Barratt J, Bailey EM, Buck KS, et al. Exaggerated systemic antibody response to mucosal Helicobacter pylori infection in IgA nephropathy. Am J Kidney Dis 1999; 33:1049.
  34. de Fijter JW, Eijgenraam JW, Braam CA, et al. Deficient IgA1 immune response to nasal cholera toxin subunit B in primary IgA nephropathy. Kidney Int 1996; 50:952.
  35. Layward L, Allen AC, Hattersley JM, et al. Response to mucosal antigen challenge in IgA nephropathy. Exp Nephrol 1995; 3:300.
  36. Béné MC, Faure GC, Hurault de Ligny B, de March AK. Clinical involvement of the tonsillar immune system in IgA nephropathy. Acta Otolaryngol Suppl 2004; :10.
  37. Xie Y, Chen X, Nishi S, et al. Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy. Kidney Int 2004; 65:1135.
  38. Roodnat JI, de Fijter JW, van Kooten C, et al. Decreased IgA1 response after primary oral immunization with live typhoid vaccine in primary IgA nephropathy. Nephrol Dial Transplant 1999; 14:353.
  39. Yamada K, Kobayashi N, Ikeda T, et al. Down-regulation of core 1 beta1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol Dial Transplant 2010; 25:3890.
  40. Yuling H, Ruijing X, Xiang J, et al. CD19+CD5+ B cells in primary IgA nephropathy. J Am Soc Nephrol 2008; 19:2130.
  41. Roccatello D, Picciotto G, Coppo R, et al. The fate of aggregated immunoglobulin A injected in IgA nephropathy patients and healthy controls. Am J Kidney Dis 1991; 18:20.
  42. Monteiro RC, Van De Winkel JG. IgA Fc receptors. Annu Rev Immunol 2003; 21:177.
  43. Grossetête B, Launay P, Lehuen A, et al. Down-regulation of Fc alpha receptors on blood cells of IgA nephropathy patients: evidence for a negative regulatory role of serum IgA. Kidney Int 1998; 53:1321.
  44. van Zandbergen G, van Kooten C, Mohamad NK, et al. Reduced binding of immunoglobulin A (IgA) from patients with primary IgA nephropathy to the myeloid IgA Fc-receptor, CD89. Nephrol Dial Transplant 1998; 13:3058.
  45. Hotta O, Furuta T, Chiba S, et al. Regression of IgA nephropathy: a repeat biopsy study. Am J Kidney Dis 2002; 39:493.
  46. Cuevas X, Lloveras J, Mir M, et al. Disappearance of mesangial IgA deposits from the kidneys of two donors after transplantation. Transplant Proc 1987; 19:2208.
  47. Haddad E, Moura IC, Arcos-Fajardo M, et al. Enhanced expression of the CD71 mesangial IgA1 receptor in Berger disease and Henoch-Schönlein nephritis: association between CD71 expression and IgA deposits. J Am Soc Nephrol 2003; 14:327.
  48. Gómez-Guerrero C, Duque N, Egido J. Mesangial cells possess an asialoglycoprotein receptor with affinity for human immunoglobulin A. J Am Soc Nephrol 1998; 9:568.
  49. McDonald KJ, Cameron AJ, Allen JM, Jardine AG. Expression of Fc alpha/mu receptor by human mesangial cells: a candidate receptor for immune complex deposition in IgA nephropathy. Biochem Biophys Res Commun 2002; 290:438.
  50. Barratt J, Greer MR, Pawluczyk IZ, et al. Identification of a novel Fcalpha receptor expressed by human mesangial cells. Kidney Int 2000; 57:1936.
  51. Gómez-Guerrero C, López-Armada MJ, González E, Egido J. Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF-alpha and IL-6, and proliferation. J Immunol 1994; 153:5247.
  52. Moura IC, Centelles MN, Arcos-Fajardo M, et al. Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med 2001; 194:417.
  53. Moura IC, Arcos-Fajardo M, Sadaka C, et al. Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J Am Soc Nephrol 2004; 15:622.
  54. Moura IC, Arcos-Fajardo M, Gdoura A, et al. Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy. J Am Soc Nephrol 2005; 16:2667.
  55. Jennette JC, Wieslander J, Tuttle R, Falk RJ. Serum IgA-fibronectin aggregates in patients with IgA nephropathy and Henoch-Schönlein purpura: diagnostic value and pathogenic implications. The Glomerular Disease Collaborative Network. Am J Kidney Dis 1991; 18:466.
  56. Zheng F, Kundu GC, Zhang Z, et al. Uteroglobin is essential in preventing immunoglobulin A nephropathy in mice. Nat Med 1999; 5:1018.
  57. Szelestei T, Bähring S, Kovács T, et al. Association of a uteroglobin polymorphism with rate of progression in patients with IgA nephropathy. Am J Kidney Dis 2000; 36:468.
  58. Coppo R, Chiesa M, Cirina P, et al. In human IgA nephropathy uteroglobin does not play the role inferred from transgenic mice. Am J Kidney Dis 2002; 40:495.
  59. Narita I, Saito N, Goto S, et al. Role of uteroglobin G38A polymorphism in the progression of IgA nephropathy in Japanese patients. Kidney Int 2002; 61:1853.
  60. Kim YS, Kang D, Kwon DY, et al. Uteroglobin gene polymorphisms affect the progression of immunoglobulin A nephropathy by modulating the level of uteroglobin expression. Pharmacogenetics 2001; 11:299.
  61. Yong D, QingQing W, Hua L, et al. Association of uteroglobin G38A polymorphism with IgA nephropathy: a meta-analysis. Am J Kidney Dis 2006; 48:1.
  62. Lai KN, Tang SC, Guh JY, et al. Polymeric IgA1 from patients with IgA nephropathy upregulates transforming growth factor-beta synthesis and signal transduction in human mesangial cells via the renin-angiotensin system. J Am Soc Nephrol 2003; 14:3127.
  63. Del Prete D, Gambaro G, Lupo A, et al. Precocious activation of genes of the renin-angiotensin system and the fibrogenic cascade in IgA glomerulonephritis. Kidney Int 2003; 64:149.
  64. Lai KN, Chan LY, Tang SC, et al. Mesangial expression of angiotensin II receptor in IgA nephropathy and its regulation by polymeric IgA1. Kidney Int 2004; 66:1403.
  65. Miyake-Ogawa C, Miyazaki M, Abe K, et al. Tissue-specific expression of renin-angiotensin system components in IgA nephropathy. Am J Nephrol 2005; 25:1.
  66. van den Dobbelsteen ME, van der Woude FJ, Schroeijers WE, et al. Binding of dimeric and polymeric IgA to rat renal mesangial cells enhances the release of interleukin 6. Kidney Int 1994; 46:512.
  67. Horii Y, Iwano M, Hirata E, et al. Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis. Kidney Int Suppl 1993; 39:S71.
  68. Floege J, van Roeyen C, Boor P, Ostendorf T. The role of PDGF-D in mesangioproliferative glomerulonephritis. Contrib Nephrol 2007; 157:153.
  69. Terada Y, Yamada T, Nakashima O, et al. Expression of PDGF and PDGF receptor mRNA in glomeruli in IgA nephropathy. J Am Soc Nephrol 1997; 8:817.
  70. Rauterberg EW, Lieberknecht HM, Wingen AM, Ritz E. Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis. Kidney Int 1987; 31:820.
  71. O'Donoghue DJ, Darvill A, Ballardie FW. Mesangial cell autoantigens in immunoglobulin A nephropathy and Henoch-Schönlein purpura. J Clin Invest 1991; 88:1522.
  72. Lai KN, Leung JC, Chan LY, et al. Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy. Nephrol Dial Transplant 2009; 24:62.
  73. Lai KN, Leung JC, Chan LY, et al. Activation of podocytes by mesangial-derived TNF-alpha: glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol 2008; 294:F945.
  74. Ye ZC, Wang C, Tang Y, et al. Serum IgA1 from patients with IgA nephropathy up-regulates integrin-linked kinase synthesis and inhibits adhesive capacity in podocytes through indirect pathways. Clin Invest Med 2009; 32:E20.
  75. Wang C, Ye Z, Peng H, et al. Effect of aggregated immunoglobulin A1 from immunoglobulin A nephropathy patients on nephrin expression in podocytes. Nephrology (Carlton) 2009; 14:213.
  76. Hill GS, Karoui KE, Karras A, et al. Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. I. Immunohistochemical studies. Kidney Int 2011; 79:635.
  77. El Karoui K, Hill GS, Karras A, et al. Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies. Kidney Int 2011; 79:643.
  78. Cook HT. Focal segmental glomerulosclerosis in IgA nephropathy: a result of primary podocyte injury? Kidney Int 2011; 79:581.
  79. Maillard N, Wyatt RJ, Julian BA, et al. Current Understanding of the Role of Complement in IgA Nephropathy. J Am Soc Nephrol 2015; 26:1503.
  80. Hisano S, Matsushita M, Fujita T, et al. Mesangial IgA2 deposits and lectin pathway-mediated complement activation in IgA glomerulonephritis. Am J Kidney Dis 2001; 38:1082.
  81. Roos A, Rastaldi MP, Calvaresi N, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 2006; 17:1724.
  82. Matsuda M, Shikata K, Wada J, et al. Deposition of mannan binding protein and mannan binding protein-mediated complement activation in the glomeruli of patients with IgA nephropathy. Nephron 1998; 80:408.
  83. Seelen MA, Roos A, Daha MR. Role of complement in innate and autoimmunity. J Nephrol 2005; 18:642.
  84. Zwirner J, Burg M, Schulze M, et al. Activated complement C3: a potentially novel predictor of progressive IgA nephropathy. Kidney Int 1997; 51:1257.
  85. Montinaro V, Gesualdo L, Ranieri E, et al. Renal cortical complement C3 gene expression in IgA nephropathy. J Am Soc Nephrol 1997; 8:415.
  86. Russell MW, Mestecky J, Julian BA, Galla JH. IgA-associated renal diseases: antibodies to environmental antigens in sera and deposition of immunoglobulins and antigens in glomeruli. J Clin Immunol 1986; 6:74.
  87. Sharmin S, Shimizu Y, Hagiwara M, et al. Staphylococcus aureus antigens induce IgA-type glomerulonephritis in Balb/c mice. J Nephrol 2004; 17:504.
  88. Koyama A, Sharmin S, Sakurai H, et al. Staphylococcus aureus cell envelope antigen is a new candidate for the induction of IgA nephropathy. Kidney Int 2004; 66:121.
  89. Nasr SH, Markowitz GS, Whelan JD, et al. IgA-dominant acute poststaphylococcal glomerulonephritis complicating diabetic nephropathy. Hum Pathol 2003; 34:1235.
  90. Suzuki S, Nakatomi Y, Sato H, et al. Haemophilus parainfluenzae antigen and antibody in renal biopsy samples and serum of patients with IgA nephropathy. Lancet 1994; 343:12.
  91. Waldo FB, Britt WJ, Tomana M, et al. Non-specific mesangial staining with antibodies against cytomegalovirus in immunoglobulin-A nephropathy. Lancet 1989; 1:129.
  92. Park JS, Song JH, Yang WS, et al. Cytomegalovirus is not specifically associated with immunoglobulin A nephropathy. J Am Soc Nephrol 1994; 4:1623.
  93. Satoskar AA, Nadasdy G, Plaza JA, et al. Staphylococcus infection-associated glomerulonephritis mimicking IgA nephropathy. Clin J Am Soc Nephrol 2006; 1:1179.
  94. Floege J, Burg M, Al Masri AN, et al. Expression of interferon-inducible Mx-proteins in patients with IgA nephropathy or Henoch-Schönlein purpura. Am J Kidney Dis 1999; 33:434.
  95. Kiryluk K, Li Y, Scolari F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 2014; 46:1187.
  96. Frimat L, Kessler M. Controversies concerning the importance of genetic polymorphism in IgA nephropathy. Nephrol Dial Transplant 2002; 17:542.
  97. Julian BA, Quiggins PA, Thompson JS, et al. Familial IgA nephropathy. Evidence of an inherited mechanism of disease. N Engl J Med 1985; 312:202.
  98. Schena FP. Immunogenetic aspects of primary IgA nephropathy. Kidney Int 1995; 48:1998.
  99. Scolari F, Amoroso A, Savoldi S, et al. Familial clustering of IgA nephropathy: further evidence in an Italian population. Am J Kidney Dis 1999; 33:857.
  100. Hsu SI, Ramirez SB, Winn MP, et al. Evidence for genetic factors in the development and progression of IgA nephropathy. Kidney Int 2000; 57:1818.
  101. Schena FP, Cerullo G, Rossini M, et al. Increased risk of end-stage renal disease in familial IgA nephropathy. J Am Soc Nephrol 2002; 13:453.
  102. Gharavi AG, Yan Y, Scolari F, et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet 2000; 26:354.
  103. Bisceglia L, Cerullo G, Forabosco P, et al. Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci. Am J Hum Genet 2006; 79:1130.
  104. Paterson AD, Liu XQ, Wang K, et al. Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36. J Am Soc Nephrol 2007; 18:2408.
  105. Karnib HH, Sanna-Cherchi S, Zalloua PA, et al. Characterization of a large Lebanese family segregating IgA nephropathy. Nephrol Dial Transplant 2007; 22:772.
  106. Liu XQ, Paterson AD, He N, et al. IL5RA and TNFRSF6B gene variants are associated with sporadic IgA nephropathy. J Am Soc Nephrol 2008; 19:1025.
  107. Miyata T, Nangaku M, Suzuki D, et al. A mesangium-predominant gene, megsin, is a new serpin upregulated in IgA nephropathy. J Clin Invest 1998; 102:828.
  108. Li YJ, Du Y, Li CX, et al. Family-based association study showing that immunoglobulin A nephropathy is associated with the polymorphisms 2093C and 2180T in the 3' untranslated region of the Megsin gene. J Am Soc Nephrol 2004; 15:1739.
  109. Xia Y, Li Y, Du Y, et al. Association of MEGSIN 2093C-2180T haplotype at the 3' untranslated region with disease severity and progression of IgA nephropathy. Nephrol Dial Transplant 2006; 21:1570.
  110. Xia YF, Huang S, Li X, et al. A family-based association study of megsin A23167G polymorphism with susceptibility and progression of IgA nephropathy in a Chinese population. Clin Nephrol 2006; 65:153.
  111. Suzuki D, Miyata T, Nangaku M, et al. Expression of megsin mRNA, a novel mesangium-predominant gene, in the renal tissues of various glomerular diseases. J Am Soc Nephrol 1999; 10:2606.
  112. Hsu SI. Racial and genetic factors in IgA nephropathy. Semin Nephrol 2008; 28:48.
  113. Li GS, Zhang H, Lv JC, et al. Variants of C1GALT1 gene are associated with the genetic susceptibility to IgA nephropathy. Kidney Int 2007; 71:448.
  114. Pirulli D, Crovella S, Ulivi S, et al. Genetic variant of C1GalT1 contributes to the susceptibility to IgA nephropathy. J Nephrol 2009; 22:152.
  115. Malycha F, Eggermann T, Hristov M, et al. No evidence for a role of cosmc-chaperone mutations in European IgA nephropathy patients. Nephrol Dial Transplant 2009; 24:321.